Application of CRUSADE score for evaluating of risk of gastrointestinal bleeding due to antiplatelet agents
10.3760/cma.j.issn.1008-5734.1014.04.006
- VernacularTitle:CRUSADE评分在抗血小板药物致消化道出血风险评估中的应用
- Author:
Junan SUN
1
;
Zongling XIA
;
Can LUO
Author Information
1. 315314,浙江省慈溪市第三人民医院药剂科
- Publication Type:Journal Article
- Keywords:
Platelet aggregation inhibitors;
Gastrointestinal homorrhage;
Evaluation studies
- From:
Adverse Drug Reactions Journal
2014;(4):209-212
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the role of CRUSADE score for evaluating the risk of gastrointestinal bleeding due to antiplatelet agents. Methods The hospitalized patients with coronary heart disease and received antiplatelet therapy for more than 1 year before hospitalization in department of internal medicine in the Third People's Hospital of Cixi,Zhejiang Province from September 1010 to September 1013 were enrolled into the study. The patients were divided into the gastrointestinal bleeding group and the non-gastrointestinal bleeding group according to whether gastrointestinal bleeding occurred due to antiplatelet agents. The CRUSADE score was evaluated in the 1 groups and the relationship between the CRUSADE score and gastrointestinal bleeding was analyzed. Results A total of 787 patients with coronary heart disease who received antiplatelet therapy more than 1 year were collected. Forty patients with gastrointestinal bleeding were enrolled into the gastrointestinal bleeding group. One hundred and sixty patients were enrolled into the non-gastrointestinal bleeding group by equidistant sampling method randomly. The gastrointestinal bleeding group comprised 31 male and 9 female with age from 45 to 88( 71 ± 9 ) years. The non-gastrointestinal bleeding group comprised 100 male and 60 female with age from 36 to 89(65 ± 13)years. There was statistically significant difference in age between the 1 groups(P ﹤0. 05). The percentage of cases of receiving aspirin enteric-coated tablets,clopidogrel hydrogen sulfate tablets,and both the above-mentioned drugs in the gastrointestinal bleeding group and the non-gastrointestinal bleeding group were 55%(11/40),10%(4/40),35%(14/40)and 54%(86/160),7%(11/160),39%(63/160),respectively. The difference was not statistically significant(P ﹥0. 05). The percentage of cases who had history of gastroin-testinal bleeding and peptic ulcer in the gastrointestinal bleeding group and the non-gastrointestinal bleeding group were 30. 0%(11/40)and 11. 9%(19/160),respectively. The difference was statistically significant(P ﹤0. 05). There were 17. 5%(11/40)and 17. 5%(11/40)cases with the results of CRUSADE score at high risk and very high risk in the gastrointestinal bleeding group,8. 1%(13/160)and 10. 6%( 17/160 ) cases in the non-gastrointestinal bleeding group,respectively. The difference was statistically significant(P﹤0. 05). Conclusions CRUSADE score can help to evaluate the risk of gastrointestinal bleeding in patients with coronary heart disease who received antiplatelet therapy. It is suggested that the patients with coronary heart disease as well as the CRUSADE score of high risk and very high risk should receive the combination of antiplatelet agents and the proton pump inhibitor,in order to prevent or reduce the gastroin-testinal bleeding.
